ArticleMolecular vision2008
Protective effects of (-)-epigallocatechin gallate on UVA-induced damage in ARPE19 cells.
Article in Molecular vision, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 57 citations in OpenAlex.
- rAAV-mediated multi-miRNA delivery targeting MAPK pathway suppresses laser-induced choroidal neovascularization in mice.Molecular therapy. Nucleic acids · 2026Article
- Mitochondrial dynamics and their role in the pathogenesis of age-related macular degeneration: A comprehensive review.Redox biology · 2026Review
- Phlorizin Protects Against Oxidative Stress and Inflammation in Age-Related Macular Degeneration Model.Biomolecules · 2025Article
- The Role of the Mitogen-Activated Protein Kinase Pathway in the Development of Laser-Induced Choroidal Neovascularization.International journal of molecular sciences · 2025Article
- A review on eye diseases induced by blue light: pathology, model, active ingredients and mechanisms.Frontiers in pharmacology · 2025Review
- Health Benefits of Epigallocatechin Gallate and Forskolin with a Special Emphasis on Glaucoma and Other Retinal Diseases.Medicina (Kaunas, Lithuania) · 2024Review
- Potential therapeutic effects of green tea (Heliyon · 2024Review
- Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration.Nutrients · 2023Review
- Pharmacotherapy and Nutritional Supplements for Neovascular Eye Diseases.Medicina (Kaunas, Lithuania) · 2023Review
- Review
- Crocetin Prevents RPE Cells from Oxidative Stress through Protection of Cellular Metabolic Function and Activation of ERK1/2.International journal of molecular sciences · 2020Article
- Proteomic analysis of retinal pigment epithelium cells after exposure to UVA radiation.BMC ophthalmology · 2019Article
- Dietary Polyphenols in Age-Related Macular Degeneration: Protection against Oxidative Stress and Beyond.Oxidative medicine and cellular longevity · 2019Review
- HBV infection increases the risk of macular degeneration: the roles of HBx-mediated sensitization of retinal pigment epithelial cells to UV and blue light irradiation.Journal of translational medicine · 2018Article
- Targeting MAPK Signaling in Age-Related Macular Degeneration.Ophthalmology and eye diseases · 2016Review
- Protective effects of resveratrol against UVA-induced damage in ARPE19 cells.International journal of molecular sciences · 2015Article
- Effect of curcumin on aging retinal pigment epithelial cells.Drug design, development and therapy · 2015Article
- Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRβ, PI3K/Akt and MAPK pathways.PloS one · 2013Article
- DJ-1-dependent regulation of oxidative stress in the retinal pigment epithelium (RPE).PloS one · 2013Article
- Systems biology-based analysis implicates a novel role for vitamin D metabolism in the pathogenesis of age-related macular degeneration.Human genomics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOxidative injury to the retinal pigment epithelium (RPE) has been proposed to play a contributing role in age-related macular degeneration (AMD). Exposure to solar ultraviolet (UV) radiation is believed to cause the production of reactive oxygen species (ROS), which may cause oxidative damage to RPE cells. Studies have shown that (-)-epigallocatechin gallate (EGCG), an abundant and active component in green tea, can protect several cell types from oxidative stress. It may be useful in the prevention of early AMD.
methodsTo determine whether EGCG protects RPE cells from UVA-induced damage, we used a cell viability assay to determine the viability of UVA-treated cells. Intracellular H(2)O(2) levels were measured by flow cytometry. Western blotting was used to detect UVA-induced signaling pathways.
resultsThe results indicated that EGCG inhibits UVA-induced RPE cell death. In addition, intracellular H(2)O(2) generation in RPE cells irradiated by UVA was inhibited by EGCG in a concentration-dependent manner. EGCG also inhibited UVA-induced extracullar signal-regulated kinase (ERK) and c-jun-NH2 terminal kinase (JNK) activation in RPE cells while a higher concentration of EGCG had an inhibitory effect on UVA-induced p38 activation. Finally, we investigated cyclooxygenase-2 (COX-2) expression in RPE cells exposed to UVA radiation, and EGCG was found to also have inhibited UVA-induced COX-2 expression.
conclusionsTaken together, our results demonstrate that EGCG inhibits UVA-induced H(2)O(2) production, mitogen-activating protein kinase activation, and expression of COX-2. Moreover, it enhances RPE cell survival after UVA exposure. This suggests EGCG is effective in preventing UVA-induced damage in RPE cells and may be suitable for further developments as a chemoprotective factor for the primary prevention of early AMD.
Indexed as
Identifiers
19119326PMC2612705W2096953583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.